VRDN Apr 2025 7.500 put
| Previous close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.1000 |
| Ask | 0.7500 |
| Strike | 7.50 |
| Expiry date | 2025-04-17 |
| Day's range | 0.8000 - 0.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
Business WireViridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
WALTHAM, Mass., September 12, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferred stock. Viridian is selling a total of 10,666,600 shares of common stock at a public offering pric
Business WireViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
WALTHAM, Mass., September 10, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian in
Business WireViridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
WALTHAM, Mass., September 10, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmune condition cha
